Bridget E. Bunner

Array ( [id] => 17548138 [patent_doc_number] => 20220119479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => HALF-LIFE EXTENDED IMMTAC BINDING CD3 AND A HLA-A*02 RESTRICTED PEPTIDE [patent_app_type] => utility [patent_app_number] => 17/427581 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019107 [patent_doc_number] => 20220370606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => Combination Treatments Of Cancer Comprising A TLR Agonist [patent_app_type] => utility [patent_app_number] => 17/415348 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27875 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17386914 [patent_doc_number] => 20220034766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => IMMUNOHISTOCHEMICAL STAINING FOR GSK-3 [patent_app_type] => utility [patent_app_number] => 17/312590 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343677 [patent_doc_number] => 20220010008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => ANTI-HUMAN INTERLEUKIN 5(IL-5) MONOCLONAL ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/413045 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20872 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221266 [patent_doc_number] => 20200246382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/711180 [patent_app_country] => US [patent_app_date] => 2019-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16711180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399596 [patent_doc_number] => 20220041686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => REGULATABLE CELL SURFACE RECEPTORS AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/299239 [patent_app_country] => US [patent_app_date] => 2019-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -127 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061015 [patent_doc_number] => 10689439 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => Optimized anti-TL1A antibodies [patent_app_type] => utility [patent_app_number] => 16/694814 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 49 [patent_no_of_words] => 38422 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16694814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389572 [patent_doc_number] => 20200330513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => T Cell Modulator [patent_app_type] => utility [patent_app_number] => 16/695170 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16695170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18070610 [patent_doc_number] => 11529426 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Methods and compositions for targeting tissue lesions [patent_app_type] => utility [patent_app_number] => 16/686708 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 21132 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16686708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17491490 [patent_doc_number] => 11280787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-22 [patent_title] => Inflammasome activation in myelodysplastic syndromes [patent_app_type] => utility [patent_app_number] => 16/679684 [patent_app_country] => US [patent_app_date] => 2019-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 117 [patent_no_of_words] => 14768 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15862925 [patent_doc_number] => 20200138866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => NON-NATURAL NKG2D RECEPTORS THAT DO NOT DIRECTLY SIGNAL THE CELLS TO WHICH THEY ARE ATTACHED [patent_app_type] => utility [patent_app_number] => 16/674705 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16674705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586521 [patent_doc_number] => 20200069795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING INNATE IMMUNITY IN A SUBJECT FOR TREATMENT OF INFECTIONS AND CANCER AND OTHER ACUTE AND CHRONIC CONDITIONS OF THE EYE [patent_app_type] => utility [patent_app_number] => 16/670785 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18147643 [patent_doc_number] => 20230021500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS [patent_app_type] => utility [patent_app_number] => 17/289992 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20254814 [patent_doc_number] => 12427147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Retinal ganglion cell death inhibitor [patent_app_type] => utility [patent_app_number] => 17/289201 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 6802 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17275852 [patent_doc_number] => 20210382050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => METHOD FOR MONITORING AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 17/286154 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33262 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17260046 [patent_doc_number] => 20210373031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => METHOD FOR DETERMINING GLOMERULAR FILTRATION ABILITY [patent_app_type] => utility [patent_app_number] => 17/286359 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17286359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493173 [patent_doc_number] => 20200046775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => COMPOSITIONS AND METHODS FOR EXPANSION OF EMBRYONIC HEMATOPOIETIC STEM CELLS [patent_app_type] => utility [patent_app_number] => 16/656342 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16656342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20076313 [patent_doc_number] => 12350348 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Compounds and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 17/284379 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 44 [patent_no_of_words] => 12488 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15290739 [patent_doc_number] => 20190388505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => METHODS AND COMPOSITIONS FOR IMMUNOMODULATION [patent_app_type] => utility [patent_app_number] => 16/561177 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16561177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408065 [patent_doc_number] => 20200024354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/547221 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16547221 [rel_patent_id] =>[rel_patent_doc_number] =>)